Ongoing activation of the haemostatic system and continuous inflammatory processes contribute to atherosclerotic progression and to the occurrence of atherothrombotic events in PAD.
ID
Bron
Verkorte titel
Aandoening
ENG:
- Atherosclerosis
- Atherothrombosis
- Peripheral artery disease
- Peripheral vascular disease
- PAD
- Cardiovascular disease
NL
- Atherosclerose
- Atherothrombose
- Perifeer vaatlijden
- Hart-en vaatziekten
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Number and type of atherothrombotic events: Coronary artery disease, myocardial infarction, stroke, limb ischemia, all-cause and cardiovascular mortality.
Achtergrond van het onderzoek
Cardiovascular disease is the number one cause of death in Europe. Peripheral artery disease is a collective name for all processes obstructing blood flow in arteries outside of the heart. It has been suggested in several studies that ongoing activation of the haemostatic system may contribute to atherosclerotic progression and to the occurrence of atherothrombotic events in peripheral artery disease.
Doel van het onderzoek
Ongoing activation of the haemostatic system and continuous inflammatory processes contribute to atherosclerotic progression and to the occurrence of atherothrombotic events in PAD.
Onderzoeksopzet
- 0 months
- 3 months
- 6 months
- 12 months
Onderzoeksproduct en/of interventie
Not applicable
Publiek
B. Kremer
Maastricht University Medical Centre
Maastricht 6202 AZ
The Netherlands
+31 (0)43 3877599
jw.brunings@mumc.nl
Wetenschappelijk
B. Kremer
Maastricht University Medical Centre
Maastricht 6202 AZ
The Netherlands
+31 (0)43 3877599
jw.brunings@mumc.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
- Patients diagnosed with peripheral artery disease, both new patients and patients currently in follow-up
- Patients who signed declaration of consent
- Patients who are at least 18 years of age and compos mentis
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
- Usage of therapeutic doses of anticoagulants (vitamin K antagonists, direct oral anticoagulants, low molecular weight heparins)
- Pregnancy, oral contraceptives, hormone replacement therapy
- Chronic inflammatory diseases
- Anti-phospholipid syndrome
- Active malignancy
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL7045 |
| NTR-old | NTR7250 |
| CCMO | NL63235.068.17 |
| OMON | NL-OMON55822 |